Skip to main content
OpenTrials

Clinical trial condition

Diffuse Midline Glioma, H3 K27M-Mutant

Explore clinical trials studying Diffuse Midline Glioma, H3 K27M-Mutant. Study availability and eligibility vary by location and protocol.

21 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Midline Glioma, H3 K27M-Mutant trial results

Recruiting

FUS Etoposide for DMG

NCT05762419

Conditions
Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +16 more
Locations
  • Columbia University Irving Medical Center New York, United States
View Trial Details
Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +30 more
Locations
  • Innsbruck Universitaetsklinik Innsbruck, Austria
  • Universitaetsklinikum Wien - AKH unikliniken Vienna, Austria
  • Onze Lieve Vrouw Ziekenhuis Aalst, Belgium
  • Institut Jules Bordet Anderlecht, Belgium
View all 42 locations
View Trial Details
Completed

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230

Conditions
Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +16 more
Locations
  • Rady Children's Hospital-San Diego San Diego, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
View all 15 locations
View Trial Details

Related conditions